These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 27288039

  • 1. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M, Lingtsang RD, Tiberi S, Enwerem M, D'Ambrosio L, Sadutshang TD, Centis R, Migliori GB.
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bedaquiline plus delamanid for XDR tuberculosis.
    Lachâtre M, Rioux C, Le Dû D, Fréchet-Jachym M, Veziris N, Bouvet E, Yazdanpanah Y.
    Lancet Infect Dis; 2016 Mar; 16(3):294. PubMed ID: 26973310
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
    Shah I, Gandhi S, Shetty NS.
    Pediatr Infect Dis J; 2020 Jun; 39(6):512-513. PubMed ID: 32032176
    [Abstract] [Full Text] [Related]

  • 6. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.
    Int J Mol Sci; 2017 Feb 07; 18(2):. PubMed ID: 28178199
    [Abstract] [Full Text] [Related]

  • 7. Compassionate and optimum use of new tuberculosis drugs.
    Matteelli A, D'Ambrosio L, Centis R, Tadolini M, Migliori GB.
    Lancet Infect Dis; 2015 Oct 07; 15(10):1131-1132. PubMed ID: 26461941
    [No Abstract] [Full Text] [Related]

  • 8. Compassionate and optimum use of new tuberculosis drugs.
    Reed C, Mason L, Cox H, Seaworth B, Lessem E, Furin J.
    Lancet Infect Dis; 2015 Oct 07; 15(10):1131. PubMed ID: 26461942
    [No Abstract] [Full Text] [Related]

  • 9. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E, Cox V, Furin J.
    Lancet Respir Med; 2017 Oct 07; 5(10):772-774. PubMed ID: 28887015
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.
    Eur Respir J; 2018 Jul 07; 52(1):. PubMed ID: 29903862
    [No Abstract] [Full Text] [Related]

  • 12. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E, Ferlazzo G, Hewison C, De Azevedo V, Isaakidis P.
    Lancet Infect Dis; 2019 May 07; 19(5):470. PubMed ID: 31034392
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.
    Lancet Infect Dis; 2018 May 07; 18(5):536-544. PubMed ID: 29452942
    [Abstract] [Full Text] [Related]

  • 16. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
    Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC.
    N Engl J Med; 2015 Nov 12; 373(20):1986-8. PubMed ID: 26559594
    [Abstract] [Full Text] [Related]

  • 17. Delamanid for Extensively Drug-Resistant Tuberculosis.
    Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H.
    N Engl J Med; 2015 Jul 16; 373(3):291-2. PubMed ID: 26176402
    [No Abstract] [Full Text] [Related]

  • 18. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
    Hafkin J, Hittel N, Martin A, Gupta R.
    Eur Respir J; 2019 Jan 16; 53(1):. PubMed ID: 30361253
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G, AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team.
    Lancet Infect Dis; 2021 Jul 16; 21(7):975-983. PubMed ID: 33587897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.